Exiris

Executive Summary

Exiris is a private Italian biotechnology company based in Milan, founded in 2015. The company leverages multiple platform technologies for target identification and validation, with a focus on developing novel antibody and drug conjugate therapeutics. Its primary platforms include a cancer stem cell platform, a drug conjugate technology, and an antibody ID technology. Exiris aims to address unmet medical needs in oncology by targeting cancer stem cells, which are implicated in tumor initiation, recurrence, and resistance. The company's integrated approach combines proprietary target discovery with antibody engineering and conjugation technologies to create next-generation biologics. Despite limited public information, Exiris represents an early-stage player in the European biotech landscape, with potential for growth if its platforms yield viable candidates. The company operates in a competitive field but differentiates itself through its focus on cancer stem cells and its modular technology suite.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing or preclinical data release40% success
• Q2 2027Strategic partnership or licensing deal for platform technology30% success
• H2 2027Series A or Series B funding round50% success